Nureca Ltd
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
- Market Cap ₹ 293 Cr.
- Current Price ₹ 308
- High / Low ₹ 376 / 200
- Stock P/E 111
- Book Value ₹ 192
- Dividend Yield 0.00 %
- ROCE 2.07 %
- ROE 0.16 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Promoter holding has increased by 2.59% over last quarter.
Cons
- The company has delivered a poor sales growth of -7.15% over past five years.
- Company has a low return on equity of -0.51% over last 3 years.
- Earnings include an other income of Rs.6.69 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 5m | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 1 | 99 | 213 | 256 | 112 | 95 | 115 | 147 | 174 | |
| Sales growth | +2,850% | +24% | +13,521% | +115% | +20% | -56% | -16% | +21% | +28% | +33% | |
| 0 | 1 | 1 | 90 | 152 | 200 | 127 | 106 | 124 | 150 | 171 | |
| Operating Profit | 0 | 0 | 0 | 10 | 62 | 56 | -15 | -11 | -10 | -3 | 3 |
| OPM % | 0.0% | 3.4% | 4.1% | 10% | 29% | 22% | -14% | -12% | -8% | -1.8% | 1.6% |
| 0 | 0 | 0 | 0 | 3 | 8 | 7 | 11 | 13 | 8 | 7 | |
| Interest | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 0 | 0 | 0 | 9 | 62 | 61 | -11 | -3 | -0 | 3 | 6 |
| Tax % | 50% | 33% | 26% | 26% | 26% | -23% | -25% | 46% | 90% | ||
| 0 | 0 | 0 | 6 | 47 | 45 | -8 | -2 | -1 | 0 | 3 | |
| EPS in Rs | 0.00 | 2.00 | 2.00 | 641.00 | 46.53 | 45.31 | -8.42 | -2.44 | -0.67 | 0.31 | 2.78 |
| Dividend Payout % | 0% | 0% | 0% | 4% | 7% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | 10% |
| TTM: | 33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -64% |
| 3 Years: | 27% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -29% |
| 3 Years: | -5% |
| 1 Year: | 19% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 4% |
| 3 Years: | -1% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 0 | 0 | 0 | 15 | 153 | 194 | 185 | 183 | 182 | 168 | 174 |
| 0 | 0 | 0 | 10 | 4 | 4 | 3 | 2 | 4 | 2 | 7 | |
| 0 | 0 | 1 | 9 | 19 | 11 | 8 | 9 | 10 | 14 | 31 | |
| Total Liabilities | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 194 | 220 |
| 0 | 0 | 0 | 1 | 3 | 10 | 8 | 6 | 8 | 12 | 17 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Investments | 0 | 0 | 0 | 0 | 1 | 34 | 62 | 97 | 4 | 4 | 6 |
| 0 | 0 | 1 | 33 | 181 | 175 | 136 | 101 | 194 | 177 | 192 | |
| Total Assets | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 194 | 220 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -8 | 35 | 2 | 12 | -3 | -19 | 0 | |||
| 0 | -0 | -110 | -3 | -18 | 18 | 9 | 16 | |||
| 0 | 8 | 92 | -7 | -2 | -1 | -1 | -19 | |||
| Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 | -2 | ||
| Free Cash Flow | -0 | -8 | 35 | -4 | 12 | -4 | -23 | -5 | ||
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -81% | 81% | 35% | -107% | 40% | 183% | 4% |
Ratios
Standalone / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365 | 87 | 65 | 47 | 0 | 4 | 14 | 7 | 14 | 24 |
| Inventory Days | 0 | 101 | 590 | 93 | 135 | 174 | 154 | 156 | 163 | 162 |
| Days Payable | 233 | 849 | 33 | 32 | 13 | 23 | 27 | 26 | 23 | |
| Cash Conversion Cycle | 365 | -45 | -195 | 107 | 103 | 165 | 145 | 136 | 151 | 164 |
| Working Capital Days | 182 | -12 | -45 | 85 | 61 | 109 | 148 | 160 | 145 | 132 |
| ROCE % | 100% | 75% | 76% | 67% | 33% | -5% | -1% | 0% | 2% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cumulative Online Customer Base thousands |
|
||||||
| Manufacturing Subsidiary (NTPL) Sales INR Crore |
|||||||
| Active SKUs count |
|||||||
| Dr Trust 360 App Users millions |
|||||||
| Live Distributors count |
|||||||
| Online Revenue Contribution % |
|||||||
| Live States & Union Territories count |
|||||||
| Manufacturing Annual Capacity units |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Credit Rating
- CRISIL assigns Nureca bank facilities ratings: Rs80 crore rated BB+/Stable and A4+.
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Q2 FY27 revenue rose 55% to ₹58.53 crore; PAT increased 12% to ₹4.05 crore.
-
Board Meeting Outcome for Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September,2026
- Board approved Q2 and H1 FY26-27 unaudited standalone and consolidated results on 21 October 2026.
-
Intimation Under Regulation 30 Of The SEBI (LODR )Regulations,2015
- Nureca’s customs classification dispute closed; Rs 57.13 lakh pre-deposit adjusted as duty and interest.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from web
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
Business Overview:[1][2]
NL is a digitally first, consumer healthcare company with presence in categories such
as home diagnostics, wellness devices, and personal fitness equipment under brands like
Dr Trust and Dr Physio. The company has 277+ Active SKUs, and 7 New Products were launched during Q1FY26